ZEVRA THERAPEUTICS, INC. Q3 FY2026 earnings call

• U.S. Commercial Execution: MyPlypha achieved strong launch momentum with cumulative prescription enrollment forms reaching 197. Management notes that approximately 50% of enrollments are pediatric and 50% adult, with a significant portion being newly diagnosed patients.
• Market Size Reassessment: Based on claims data analysis and increased disease awareness, management believes the U.S. NPC patient population is larger than previous estimates (originally 300-350 diagnosed), potentially ranging up to 900 prevalent cases. This has prompted a modest expansion of the commercial team.
• Regulatory Progress (EU): The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) re-examination is ongoing. New rapporteurs have been appointed, and an ad hoc expert group will review data. A CHMP opinion is expected in Q4 2026.
• Pediatric Label Expansion: Following positive pediatric sub-study results showing safety and tolerability in infants under 24 months, Zevra plans to file a Supplemental New Drug Application (sNDA) in Q1 2027 to expand the U.S. label.
• Pipeline Update (Solipilol): Phase III DISCOVER trial for VEDS enrolled six new patients in Q3, totaling 72. Four confirmed major events occurred against a trigger threshold of 28. Management is engaging with the FDA to explore adding real-world data to accelerate development.
• Financial Position: The company holds over $270 million in cash, providing flexibility to advance commercial operations and pipeline assets without immediate capital raising needs.

Total net revenue increased 45% year-over-year to $37.8 million. U.S. product revenue from MyPlypha accounted for the vast majority of this growth at $34.0 million (approximately 90% of total revenue). Global Expanded Access Program (EAP) reimbursements contributed $3.6 million (approximately 10%), while other sources contributed $0.2 million.

• Q1 2027 sNDA Filing: Management confirmed the intention to file the supplemental NDA for pediatric expansion (under 24 months) in the first quarter of 2027.
• CHMP Opinion Timeline: Expected release of the CHMP opinion regarding Arimoclamol in Europe in Q4 2026.
• SG&A Stability: For 2027, management indicated no meaningful increases in marketing spend compared to current levels, citing a disciplined approach and right-sized commercial team despite potential market expansion.
• No Full Year Guidance Provided: Management declined to provide specific full-year 2027 SG&A or revenue guidance, noting they do not expect major changes to marketing spend but emphasizing flexibility.

• Diagnostic Uncertainty: NPC symptoms vary widely, leading to delayed diagnoses and potential misdiagnosis (e.g., as multiple sclerosis), which complicates patient identification.
• Regulatory Delays: The EU re-examination process involves procedural uncertainties, including new rapporteur appointments and expert group reviews, though opinions are still targeted for Q4.
• Competitive Dynamics: Entry of new competitors (e.g., Shinogi acquiring Intrabio) may alter market dynamics, although management views this as validating the market size rather than threatening their position.
• Data Interpretation Risks: Reliance on retrospective claims data and real-world evidence for regulatory submissions and market sizing introduces variability in projections.

Q: Analyst asked about near-term opportunities for MyPlypha given the strong cash balance and whether the sNDA filing drives these opportunities. / A: CEO confirmed that near-term opportunities are driven by the planned sNDA filing in Q1 2027 to expand the label to infants under 24 months. This strategy leverages recent pediatric safety data and strong IP protection (patents through 2041) to capture additional patient segments.